The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 20, 2021

Filed:

Jul. 20, 2017
Applicant:

The U.s.a., As Represented BY the Secretary, Department of Health and Human Services, Bethesda, MD (US);

Inventors:

Mitchell Ho, Urbana, MD (US);

Nan Li, Laurel, MD (US);

Dimiter S. Dimitrov, Pittsburgh, PA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/30 (2006.01); A61K 47/69 (2017.01); A61K 47/64 (2017.01); A61P 35/00 (2006.01); C07K 7/08 (2006.01); C07K 16/28 (2006.01);
U.S. Cl.
CPC ...
C07K 16/3053 (2013.01); A61K 47/6415 (2017.08); A61K 47/6929 (2017.08); A61P 35/00 (2018.01); C07K 7/08 (2013.01); C07K 16/2809 (2013.01);
Abstract

A panel of human variable heavy (VH) single domain monoclonal antibodies specific for cell-surface glypican-2 (GPC2) are described. Methods for the diagnosis and treatment and GPC2-positive cancer are also described. Recombinant immunotoxins comprised of a GPC2-specific VH domain antibody and a clinically used form ofexotoxin A (PE38) were generated and shown to inhibit GPC2-positive neuroblastoma tumor cell growth and inhibit neuroblastoma xenograft growth in nude mice, without significant toxicity. Chimeric antigen receptors comprising a GPC2-specific VH single domain antibody are also described. T cells expressing the GPC2-specific CARs potently killed GPC2-positive neuroblastoma cells in a dose-dependent manner.


Find Patent Forward Citations

Loading…